Posted on 21 September 2022

VIVEbiotech, one of the three only companies to obtain a PERTE

VIVEbiotech has obtained the PERTE called “Salud de Vanguardia/State-Of-The-Art Health” by the Ministry of Industry of the Spanish Government which is financed with European funds for the design and production of lentiviral vectors.

The PERTEs (Strategic Projects for Economic Recovery and Transformation) are a new instrument of public-private collaboration in which the different public administrations, companies and research centers collaborate. Their objective is to promote major initiatives that clearly contribute to the transformation of the Spanish economy.

Knowing that the criteria for declaring a PERTE are 1- contributing to economic growth and employment and 2- quantitative or qualitative importance of the projects, this demonstrates the clear commitment of the Government of Spain and the European Union to promoting advanced therapies.